Filing Analysis
Regulation FD Disclosure
Filed May 05, 2026
LOW
Precision BioSciences announced its financial results for the first quarter ended March 31, 2026. The results were disclosed via a press release furnished as an exhibit to the filing.
Key Facts
- The filing reports financial results for the fiscal quarter ended March 31, 2026.
- The report was filed on May 5, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- The filing was signed by John Alexander Kelly, Chief Financial Officer.
Regulation FD Disclosure
Filed Mar 17, 2026
LOW
Precision BioSciences hosted a Key Opinion Leader (KOL) event on March 17, 2026, to discuss the Duchenne muscular dystrophy (DMD) treatment landscape and the company's clinical progress. The event focused on the PBGENE-DMD program and the FUNCTION-DMD Phase 1/2 clinical trial.
Key Facts
- The event featured Dr. Aravindhan Veerapandiyan, a pediatric neurologist, and Pat Furlong, Founding President of Parent Project Muscular Dystrophy.
- The presentation provided an overview of the PBGENE-DMD program and the FUNCTION-DMD Phase 1/2 clinical trial.
- The company furnished the presentation materials as Exhibit 99.1.
- The event was held via live webcast on March 17, 2026, at 9:00 a.m. ET.
Regulation FD Disclosure
Filed Mar 12, 2026
LOW
Precision BioSciences, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The results were disclosed via a press release furnished as Exhibit 99.1 to the filing.
Key Facts
- Filing date: March 12, 2026
- Reporting period: Quarter and fiscal year ended December 31, 2025
- The company furnished the information under Item 2.02 (Results of Operations and Financial Condition)
- John Alexander Kelly, Chief Financial Officer, signed the report
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.